Work

Supplementary Table 3 from A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

Year: 2023

Type: supplementary-materials

Abstract: Clinical demographics and characteristics of responses in all patient on study.

DOI: 10.1158/1078-0432.22462727.v1

Authors: Eric Padron, Amy Dezern, Marcio Andrade-Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361968154

Cites:

Cited by:

Related to: 10